Medicare Enrolled
Dr. Christopher Lafargue, M.D.
Student in an Organized Health Care Education/Training Program · Fort Worth, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lafargue from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lafargue?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lafargue
Dr. Christopher Lafargue is a student in an organized health care education/training program specialist in Fort Worth, TX, with 13 years of NPI registration. Based on federal Medicare data, Dr. Lafargue performed 36,040 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Lafargue received a total of $19,847 from 14 pharmaceutical and/or device companies across 53 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lafargue is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years of NPI registration
▲ Top 1% volume in TX
$19,847 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗36,040
Medicare services
Top 1% in TX for student in an organized health care education/training program
Not available
Unique patients (not deduplicated)
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 10,300 | $43 | $138 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,400 | $0 | $5 |
| Paclitaxel chemotherapy injection | 6,636 | $0 | $8 |
| Azacitidine chemotherapy injection An injection of the medication azacitidine, measured at 1 mg per unit. |
5,500 | $0 | $13 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,205 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 680 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 640 | $1 | $114 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
251 | $8 | $20 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
223 | $12 | $108 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
209 | $10 | $64 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
205 | $8 | $36 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
205 | $103 | $707 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
202 | $96 | $368 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
185 | $2 | $300 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 172 | $20 | $128 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
114 | $23 | $157 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
113 | $6 | $431 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
81 | $57 | $211 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
69 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
67 | $49 | $313 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
65 | $11 | $96 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
65 | $68 | $250 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
64 | $51 | $344 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
49 | $22 | $161 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
42 | $1 | $8 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
40 | $10 | $75 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $136 | $3,675 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
30 | $141 | $496 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
28 | $16 | $94 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
24 | $2 | $19 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
23 | $24 | $145 |
| New patient office visit, complex (60-74 min) | 19 | $169 | $709 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
19 | $1 | $19 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $131 | $565 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
17 | $1,103 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | $84 | $657 |
| CA 19-9 tumor antigen test A blood test that measures the level of CA 19-9, a substance that can be found in the blood of some people with cancer. This quantitative analysis detects and measures the specific tumor antigen. |
12 | $20 | $128 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
11 | $19 | $99 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.4% high complexity
94.9% medium
3.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$19,847
Total received (2021-2024)
Avg $4,962/year across 4 years
Top 2% in TX for student in an organized health care education/training program
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
14
Companies
53
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,687
2023
$9,506
2022
$3,351
2021
$304
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$6,229
Eisai Inc.
$128
Merck Sharp & Dohme LLC
$60
Genmab U.S., Inc.
$56
GlaxoSmithKline, LLC.
$49
ABBVIE INC.
$46
Novartis Pharmaceuticals Corporation
$44
Medtronic, Inc.
$34
Integra LifeSciences Corporation
$23
Astellas Pharma US Inc
$19
Top 3 companies account for 96.0% of 2024 payments
All-time payments by company (2021-2024) ›
AstraZeneca Pharmaceuticals LP
$6,371
GlaxoSmithKline, LLC.
$6,084
Eisai Inc.
$3,494
Seagen Inc.
$3,072
Stryker Corporation
$429
Merck Sharp & Dohme LLC
$92
Genmab U.S., Inc.
$83
Novartis Pharmaceuticals Corporation
$69
ABBVIE INC.
$46
Medtronic, Inc.
$34
Integra LifeSciences Corporation
$23
Astellas Pharma US Inc
$19
EISAI INC.
$18
ImmunoGen, Inc.
$16
Top 3 companies account for 80.4% of all-time payments
Associated products mentioned in payments ›
CODMAN CERTAS · ELAHERE · ENHERTU · Elahere · IRIS · JEMPERLI · KEYTRUDA · LIGASURE · LYNPARZA · Lenvima · MEKINIST · SPY-PHI SYSTEM · TIVDAK · Tivdak · Veozah · ZEJULA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Student in an organized health care education/training programs in nearby ZIP areas
1,424
County median income
$81,905
Nearest hospital to ZIP centroid (approximate)
JPS HEALTH NETWORK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lafargue is a mixed practice specialist, with above-average Medicare volume (top 1% in TX).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lafargue experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Lafargue performed 10,300 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Lafargue receive payments from pharmaceutical companies?
Yes. Dr. Lafargue received a total of $19,847 from 14 companies across 53 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lafargue's costs compare to other student in an organized health care education/training programs in Fort Worth?
Dr. Lafargue's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lafargue) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Student In An Organized Health Care Education/training Programs in Fort Worth
Browse student in an organized health care education/training programs in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Student In An Organized Health Care Education/training Programs in TX
Student in an organized health care education/training programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student In An Organized Health Care Education/training Programs in TX
Which TX student in an organized health care education/training programs receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology